Mutations in the metallo-protein Cu/Zn-superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS) in humans and
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset disease in which motor neurons in the spinal cord and brain progressively deteriorate and die. Initial clinical symptoms of ALS are relatively mild, but inevitably progress to paralysis and premature death as the extent of motor neuron failure increases. Riluzole (trade name Rilutek) is the only approved treatment for ALS, but its therapeutic effects are minimal. Treatment with riluzole provides an approximate 3 month increase in patient survival and has no effect on the deterioration of muscle strength (Bensimon et al., 1994; Lacomblez et al., 1996; Miller et al., 1996) . The development of new treatment strategies for ALS is needed.
Approximately 90% of ALS cases are sporadic, and 10% are familial. Several genes are associated with the development of ALS, including TARDBP (Sreedharan et al., 2008) and C9ORF72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011) , but the gene for the ubiquitous antioxidant enzyme Cu/Zn-superoxide dismutase (SOD1) is the most widely studied to date and has provided the basis for the development of the most robust animal models of ALS. Over 100 different SOD1 mutations account for ϳ20% of familial ALS cases (Rosen et al., 1993) , and SOD1 mutations are also present in sporadic forms of the disease (Andersen et al., 2003) . Nonmutated, wild-type SOD1 is aberrantly metabolized in sporadic cases of ALS (Bosco et al., 2010) , and overexpression of wild-type SOD1 causes an ALS-like phenotype in mice that is comparable to the phenotype of ALS model mice caused by the expression of mutant SOD1 . Thus, the pathogenic role of SOD1 in ALS appears to extend beyond familial cases that involve SOD1 mutations.
Although oxidative damage is conspicuous in disease-affected tissues (Niebró j-Dobosz et al., 2004) , SOD1 mutations do not cause ALS by a loss of antioxidant function (Bruijn et al., 1998) . Motor neuron death in SOD1-associated forms of ALS therefore represents the consequences of a toxic gain of function in the mutant protein. Underscoring this, transgenic mice overexpressing mutant SOD1 develop an ALS-like phenotype that is proportional to the expression level of the mutant SOD1. Higher levels of mutant SOD1 cause earlier disease onset, more severe disease symptoms, and more rapid disease progression (Gurney et al., 1994; Wong et al., 1995; Henriques et al., 2010) . However, despite the clear link between motor neuron death and disease symptoms in SOD1-associated forms of ALS, the fundamental basis of SOD1 toxicity in ALS is not fully understood. To address this, the present study examined spinal cord tissue collected from ALS model mice (SOD1G37R; Wong et al., 1995) that had been treated with the therapeutic agent diacetyl-bis(4-methylthiosemicarbazonato)copper II [Cu II (atsm) ]. Given that the ALS-like phenotype of these mice is driven by expression of the mutant SOD1, the aim of the study was to investigate the relationship between therapeutic activity of Cu II (atsm) and its effects on SOD1.
Materials and Methods
SOD1G37R mice. SOD1G37R mice (Wong et al., 1995) were used in this study. The effects of Cu II (atsm) have been investigated previously in a G93A mouse model of ALS (Soon et al., 2011) . SOD1G37R mice purchased from The Jackson Laboratory, and a colony was maintained by breeding SOD1G37R-positive mice with nontransgenic C57BL/6 mice. Mice were housed in standard boxes (two to five mice per box) with access to food and water ad libitum. Bedding for the boxes contained only saw dust and shredded paper, with no other environmental enrichment. Mice were maintained under a 12 h light/dark cycle. Mice were genotyped using tail snips obtained from the mice at the age of weaning (ϳ3 weeks of age). The genotyping of all mice was determined using the commercial Extract-N-Amp Plant PCR Kit (Sigma), as per the manufacturer's instructions to extract DNA from the sample tissue and to prepare samples for PCR (primers and cycling steps were obtained from The Jackson Laboratory website). The PCR product was run on a 1.7% agarose gel at 100 V for 30 min and then imaged using the UVP BioDoc-It System (Pathtech).
All treatment groups contained approximately equal numbers of male and female mice. One cohort of mice was studied through to disease end stage to obtain data on locomotor function. A second cohort of mice was culled at 24 weeks of age to collect tissues for biochemical and histological analyses. All mouse procedures were approved by the Animal Ethics (atsm) . Cu II (atsm) was synthesized as previously described (Gingras et al., 1962; Blower et al., 2003) , and a suspension of the compound was prepared daily in standard suspension vehicle [SSV; 0.9% (w/v) NaCl, 0.5% (w/v) Na-carboxymethylcellulose (medium viscosity), 0.5% (v/v) hCTR1xSOD1G37R mice. The human copper transporter 1 (hCTR1) coding sequence was amplified from human fibroblast mRNA. The forward primer was used to introduce a Flag epitope just upstream from the start codon, and the reverse primer was located just after the stop codon. The PCR product was cloned into pCMB336 (Ke et al., 2006) . A 4.1 kb PvuI/StuI fragment containing the CAG promoter, the hCTR1 insert, and a polyA signal was purified and used at 2 ng/l for pronuclear microinjections in C57BL/6 females (Mouseworks, Monash University, Melbourne, Victoria, Australia). hCTR1 mice were genotyped by PCR of genomic DNA isolated from ear notches (Viagen Biotech). The detection of the hCTR1 transgene and the endogenous mCtr1 gene (as a control for the integrity of the extracted DNA) was performed with the following primers:senseoligonucleotidehCTR1#1(5Ј-TAAGTCACAAGTCAGCA TTCGC), corresponding to the coding sequence of the hCTR1 transgene and the antisense oligonucleotide SP6(2) from the vector (5Ј-GCTCTAGCATTTAGGTGACACTATAG); the sense oligonucleotide mCtr1 #2 (5Ј-GCCAAGAGACCTTTGCTCTG) and the antisense oligonucleotide mCtr1 #3 (5Ј-GCACCTTAATGTTGGGCTGT), corresponding to the 3Ј untranslated region of the endogenous mCtr1 gene. C57BL/6 mice positive for the hCTR1 transgene were backcrossed for two generations, then bother/sister mating continued for a further seven generations. Double-transgenic hCTR1xSOD1G37R mice were created by mating SOD1G37R hemizygotes with hCTR1 hemizygotes. Litters were genotyped for all possible genetic variants via PCR, as described above.
hCTR1 expression was quantified using qRT-PCR methods that were described previously (Kanninen et al., 2013) with all cDNA synthesis and qRT-PCR reagents from Life Technologies. Briefly, RNA from nontransgenic and transgenic hCTR1 mouse spinal cord tissue (5 mg) was isolated, and treated with DNase using the MagMAX-96 Total RNA Isolation Kit. RNA concentrations were quantified using the Qubit 2.0 Fluorometer, then 200 ng of RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit. Primers for hCTR1 were GCTGGAAGAAGGCAGTGGTA and GGCCACGCCATAGAGTTTG, and for mCtr1 they were TTCTTCAGGGTAGCTTCCGAGTA and CAACCTAGCGCAGGGATCT. Each 10 l reaction mix consisted of 300 nM primers, 5 l 2ϫ Power SYBR Green Master Mix, and 20 ng of cDNA template. Duplicate reactions were performed using the LightCycler 480 (Roche) and the following conditions: 10 min at 95°C, followed by 45 cycles of 15 s at 95°C, and 60°C for 60 s. Cycle threshold (Ct) values were calculated as the lowest cycle number producing an exponential increase in PCR product amplification. Samples with Ct values Ͻ30 were excluded from all analyses. The ⌬Ct method was used to normalize hCTR1 gene expression in each sample to the expression of endogenous mCtr1. To assess whether hCTR1 expression altered the expression of endogenous mCtr1, the ⌬Ct method was used to normalize mCtr1 gene expression in each sample to the expression of endogenous mActb.
Locomotor function. Mice were tested for a locomotor function using the rotarod assay. Mice were trained for 5 d before data were recorded for analysis. During the data collection phase of the study, the mice were tested on the rotarod twice a week. For SOD1G37R mice treated with Cu II (atsm), the rotation speed of the rotarod was 25 rpm, and the time that each mouse could no longer stay on the rotarod (latency to fall) was recorded up to a maximum of 180 s. For mice in the hCTR1xSOD1G37R study, the rotation speed of the rotarod accelerated from 4 to 40 rpm over 180 s. Mice were placed on the rotarod twice during each testing period, and only their maximum score recorded for analysis. Researchers performing the rotarod assay were blinded to the treatments. Mouse survival. SOD1G37R mice eventually develop limb paralysis that prevents them from accessing food and water, and individual mice in this study, regardless of treatment, were culled once they reached this stage. This stage was identified as the point at which individual mice had complete paralysis in at least one hindlimb and were unable to right themselves within 15 s after being laid down on their side. All survival data presented in this study therefore represent the age at which the mice reached this disease stage. Researchers who culled mice were blinded to the treatments and mouse genotype.
Tissue collection. Mice allocated to collecting tissues for biochemical analyses were killed when 24 weeks old. These mice were killed by intraperitoneal injection of PBS supplemented with ketamine (20 mg/ml) and xylazine (4 mg/ ml), followed by transcardial perfusion with PBS containing 0.25% phosphatase inhibitor mixture, 1% protease inhibitor (Roche), and 20 U/ml heparin. After perfusion, spinal cords and brains were removed. A small 5 mm section of the lumbar region of the spinal cord was removed and submersion fixed in 4% (v/v) paraformaldehyde, and a similar lumbar section was snap frozen on dry ice for subsequent mass spectrometry analyses. The remaining spinal cord material was snap frozen on dry ice for subsequent protein extraction and additional biochemical analyses.
SDS-PAGE. Spinal cords were homogenized using disposable polypropylene pestles for Microfuge tubes (USA Scientific) in PBS supplemented with protease and phosphatase inhibitors (Sigma), then PBS-soluble and PBSinsoluble fractions were collected by centrifugation (16,000 ϫ g, for 30 min at 4°C). After determining the protein content via the BCA Assay (Thermo Scientific), samples were prepared in a sample buffer [62.6 mM Tris, 5% (v/v) glycerol, 2% (w/v) SDS, and 0.0025% (w/v) bromophenol blue], then were loaded onto 12% NuPAGE Novex Bis-Tris gels (Life Technologies) and electrophoresed at 175 V for 60 min in MES SDS running buffer (Life Technologies). Resolved proteins were transferred to PVDF membranes, and Western blotting was performed as described previously . The primary antibodies that were used were raised to detect human SOD1 (Abcam), mouse SOD1 (Abnova), and GAP43 (Novus Biologicals). Antibody immunoreactivity was detected using enhanced chemiluminescence (ECL Advance, GE Healthcare) and a FujiFilm LAS-3000 imager. Chemiluminescence images were saved as TIFF files, and the relative intensity of immunoreactivity was determined using NIH ImageJ version 1.38x software.
Native PAGE. PBS-soluble and PBSinsoluble spinal cord extracts generated as described above were prepared in native PAGE sample buffer [100 mM Tris, 10% (v/v) glycerol, 0.0025% (w/v) bromophenol blue, pH 8.6], then resolved on 12% tris-glycine gels (Life Technologies) at 125 V for 100 min in native tris-glycine running buffer (Life Technologies) before transferring to PVDF membranes as described above. Membranes were probed using the primary antibodies A5C3, B8H10, and C4F6 (MédiMabs). All three of these antibodies were generated to specifically detect misfolded forms of human SOD1 but not natively folded wild-type SOD1, and data supporting this conformation-dependent immunoreactivity have been presented (Bosco et al., 2010; Gros-Louis et al., 2010). Immunoreactivity for these three antibodies was detected and quantified as described above. Histology. Histology was performed based on methods previously described (Li et al., 2006) . Lumbar sections of mouse spinal cord were fixed in 4% (w/v) paraformaldehyde in PBS, then were embedded in wax and transverse 5 or 20 m sections were collected on glass slides. The 20 m sections were stained for nucleic acid material using cresyl violet (700 M in dH 2 O, pH 3.8, with 1% acetic acid), then ␣-motor neurons in the ventral horn were counted using light microscopy. Thirty-six sections from spinal cord regions spanning ϳ1800 m along the longitudinal plane of the spinal cord were counted per mouse. The data presented in Figure 1B represent the total number of ␣-motor neurons counted per mouse per ventral horn. To assess the levels of Iba-1 and GFAP, 5 m sections were quenched with peroxide, blocked with 20% (v/v) serum, then were incubated with primary antibody (1:1000) overnight at 4°C. To assess the levels of human SOD1 and misfolded forms there of proteinase-K-treated, 5 m sections were blocked with 20% (v/v) serum then were incubated overnight at 4°C with primary antibodies to misfolded SOD1, as described above. Sections were developed using the universal LSABϩHRP kit (Dako), as described by the manufacturer.
Protein oxidation. PBS-soluble tissue extracts, prepared as described above, were analyzed for oxidatively modified proteins using the OxyBlot Protein Oxidation Detection Kit (Millipore). Oxidatively modified proteins were derivatized as per kit instructions then loaded onto 12% trisglycine gels (Life Technologies) before transfer to PVDF membranes as described above. Membranes were probed for derivatized proteins using kit antibodies, and oxidatively modified proteins were detected via chemiluminescence as described above.
SOD activity assay. SOD activity gels were performed as previously described (Soon et al., 2011) . Briefly, soluble samples collected from spinal cord tissue were diluted in native sample buffer, and 1 g of protein was loaded onto a native 12% tris-glycine gel. After electrophoresis, gels were immersed in nitroblue tetrazolium then developed with tetramethylethylenediamine and riboflavin in KH 2 PO 4 buffer.
Mass spectrometric quantification. The metal status and total SOD concentration was determined as described previously (Rhoads et al., 2011) with the following modifications. Mouse tissues were dissected and frozen on a plastic dissection plate placed on a block of dry ice to maintain a subzero temperature. For spinal cords, 1-to 2-mm-thick transverse sections were cut with a razor blade, laid flat on the dissection plate, and 0.3-mm-diameter punches of either dorsal or ventral gray matter (300 m biopsy punch, Zivic Instruments) were obtained. The tissue was expelled with air from the punch onto a tarred aluminum weigh boat (VWR) and then weighed to the nearest microgram using an analytical balance (model 25 automatic electrobalance, Cahn). Punch weights ranged between 90 and 200 g. The punch was then mixed with 5 l of 10 mM ammonium acetate, pH 5.1, containing 500 nM bovine SOD as an internal standard. The supernatant was then bound to an equilibrated C 4 Ziptip (Millipore) and desalted by aspirating with 10 l of deionized water, which was repeated six times. The point of the Ziptip was then pressed into PEEK tubing, leading to the electrospray ionization source of an LTQ-FT Ultra MS unit (Thermo Scientific) with an electrospray ionization interface in positive-ion mode. A second piece of PEEK tubing coming from the HPLC pump was inserted into the rear of the Ziptip, and the tip was then perfused with a mobile phase of 30% (v/v) acetonitrile/water with 100 M formic acid (at 30 ml/min). The elution of SOD occurred over 2-3 min, after which time the total ion count returned to baseline. Integration and quantitation of SOD was performed as described previously (Rhoads et al., 2011 (Rhoads et al., , 2013 .
Size exclusion chromatography inductively couple plasma mass spectrometry. Liquid chromatography coupled to inductively coupled plasma mass spectrometry (LC-ICPMS) was performed using an HPLC unit (model 1200, Agilent) equipped with binary pumps, an in-line degasser, a thermostat-controlled column compartment, a variable wavelength detector, and a temperature controlled autosampler. The HPLC was directly connected to a Teflon Mira Mist Nebulizer with PEEK tubing. An Agilent 7700 series ICPMS instrument was used as a multielemental detector and was operated in He mode (4.3 ml/min) under routine multielemental operating conditions. Samples were chromatographically separated with a BioSEC3 size exclusion column (4.6 ϫ 300 mm, 300Å; Agilent) with 200 mM ammonium nitrate, pH 8.0, at a flow rate of 0.4 ml/min (145 cm/h, 30°C). The size exclusion column was calibrated using the following molecular weight standards, and elution volume was monitored both by absorbance (280 nm) and by ICPMS (mass of each standard, element detected by ICPMS, and source of standard are shown in parentheses): thyroglobin (667 kDa; I; GE), ferritin (440 kDa; Fe; GE), catalase (232 kDa; Fe; GE), albumin (64 kDa; Fe, Cu, Zn; GE), bovine SOD1 (32 kDa; Cu, Zn; Sigma), and vitamin B 12 (1.2 kDa; Co; Sigma), and the integration time for each element was 0.2 s. A standard curve of SOD1 (bovine, Sigma) was also determined by measuring the amount of SOD protein ( 258 ϭ 10,300 M Ϫ1 cm Ϫ1 ), and the total amount of Cu and Zn was determined by bulk measure ICPMS. The standard curve was linear over the range of 1-1000 pmol SOD injected on column (r 2 Ͼ0.98). PBS-soluble spinal cord extracts (prepared as described above) containing 200 g of total protein were injected on column (ϳ20 l injections) and developed for 1.6 column volumes (8 ml).
Laser ablation inductively couple plasma mass spectrometry. Laser ablation ICPMS (LA-ICPMS) imaging mass spectrometry was performed on paraformaldehyde-fixed spinal cord transverse sections, as previously described Lear et al., 2012) . Imaging mass spectrometry is a relatively new analytical science that combines discrete solid sampling with mass specific detection. LA-ICPMS uses high-energy laser pulses to provide a source of particles for inorganic mass spectrometry, allowing spatial profiling of trace metals directly in solid samples. Quantitative images depicting the spatial distribution of metals in tissue sections are produced by rastering the laser beam across the tissue surface.
Statistical analyses. The Kolmogorov-Smirnov test for normality (with a Dallal-Wilkinson-Lilliefor-corrected p value) was applied to all datasets to test for Gaussian distribution. Normally distributed data were analyzed using the unpaired t test when comparing the mean of two datasets or a two-way ANOVA (with Bonferroni post-tests). Data that did not fit Gaussian distribution were analyzed using the Mann-Whitney test when comparing the mean of two datasets. The statistical significance of mouse survival data was determined using the Log-rank (MantelCox) test. The statistical significance of locomotor function data was determined using a two-way repeated-measures ANOVA. (Fig. 1B) , decreased levels of oxidatively modified proteins (Fig. 1C) , decreased the abundance of GFAPimmunoreactive cells (astrocytes) within spinal cord gray matter, and decreased the abundance of activated microglia (Fig. 1D) . All biochemical and histological analyses were performed on tissues collected at the mid-symptom age of 24 weeks, as indicated by the vertical dashed line in Figure 1A . Relatively modest changes in ␣-motor neuron numbers are consistent with the severity of disease symptoms at this age (Feeney et al., 2001 ).
Results

Cu
II (atsm) increases levels of mutant SOD1 in vivo by increasing the Cu content of the protein We examined whether therapeutic activity of Cu II (atsm) was related to effects on levels of mutant SOD1. Surprisingly, an increase in the mutant form of SOD1 was detected in the spinal cords of Cu II (atsm)-treated mice. This was evident via Western blot (Fig. 2 A, B) and histology (Fig. 2C) . Endogenous, wild-type mouse SOD1 was not affected by the Cu II (atsm) treatment (Fig.  2 A, B) . A substantial pool of metal-deficient SOD1 (i.e., where each monomer equivalent of SOD1 contains one Cu ion or one Zn ion, but not both) was decreased by the Cu II (atsm) treatment, whereas the increase in total SOD1 was driven by an increase in the pool of fully metallated holo-SOD1 (Fig. 2D) . Conversion of metal-deficient SOD1 to holo-SOD1 appeared to be driven by the delivery of Cu to the mutant protein as Cu-deficient SOD1 was the only form of metal-deficient SOD1 that decreased (Fig.  2E) , as indicated by the strong correlation between metal-deficient SOD1 and Cudeficient SOD1 (Fig. 2F ) . There was no correlation between metal-deficient SOD1 and Zn-deficient SOD1 (R 2 ϭ 0.003, p ϭ 0.8; data not shown). Supporting an increase in the amount of SOD1 that contained Cu, SOD activity was increased in the spinal cords of Cu II (atsm)-treated SOD1G37R mice (Fig. 2G) .
LA-ICPMS data ( Fig. 3) showed that oral treatment with Cu II (atsm) increased the Cu content of the spinal cords of nontransgenic mice 2.2-fold (Fig. 3) , and this is consistent with data showing that orally administered Cu II (atsm) penetrates CNS tissue (Soon et al., 2011; Hung et al., 2012) . The increase in spinal cord Cu was more pronounced in SOD1G37R mice (Fig. 3B) , indicating that the Cu II (atsm) had elevated penetration of CNS tissue in SOD1G37R mice or that the compound was selectively retained and/or metabolized within the CNS tissue of SOD1G37R mice. Treatment with Cu II (atsm) also increased the overall levels of Zn in spinal cords of SOD1G37R mice, but, unlike Cu, the increase in Zn was not evident in nontransgenic mice (Fig. 3) . Fe levels (Fig. 3) and Mn levels (data not shown) were not changed.
To gain further information on the Cu II (atsm)-induced changes within the pool of holo-SOD1G37R and its associated metal ions Cu and Zn, we performed size exclusion LC-ICPMS. This metalloproteomic approach revealed that Cu and Zn were both increased in SOD1 by the Cu II (atsm) treatment (Fig. 4 A, B) . The Cu/Zn ratio within the SOD1G37R calculated from these LC-ICPMS data con- firmed that SOD1G37R in the spinal cords of vehicle-treated mice was relatively Cu deficient (Fig. 4C) . The Cu II (atsm)-induced increase in the SOD1G37R Cu/Zn ratio was consistent with the LA-ICPMS data (Fig. 3) (atsm) has the capacity to increase levels of bioavailable Cu and Zn in cells in vitro . This indicates that the increase in Cu in the mutant SOD1 (Fig. 4A) (Fig. 4D) , indicating a transfer of Cu from Cu II (atsm) to the SOD1. Based on a total spinal cord wet weight of ϳ50 mg, the data in Figure 4D equate to ϳ2% of the total Cu delivered orally to the mice as Cu II (atsm) was being transferred to SOD1 in the spinal cord. 
Treatment with Cu
II (atsm) did not decrease levels of misfolded SOD1 Suboptimal metal content of SOD1 can promote SOD1 misfolding and aggregation (Lynch et al., 2004; Rumfeldt et al., 2009; Ip et al., 2011) , and misfolded and aggregated SOD1 is a consistent feature of ALS (Bruijn et al., 1998; Furukawa et al., 2006; Wang et al., 2008; Chattopadhyay and Valentine, 2009; Prudencio et al., 2009) , including sporadic ALS (Bosco et al., 2010) . Given that Cu II (atsm) improved the metal content of the mutant SOD1 (Fig. 3) , the levels of misfolded SOD1 in the spinal cords of Cu II (atsm)-treated SOD1G37R mice were assessed using three antibodies raised against misfolded SOD1 (Bosco et al., 2010; . Misfolded SOD1 was readily detectable in the soluble fraction of spinal cords from SOD1G37R mice, but the Cu II (atsm) treatment did not significantly alter its abundance (Fig. 5A-C) . The results for all three antibodies trended toward an increase in misfolded SOD1 in the soluble fraction in the Cu II (atsm)-treated mice, and this was supported by histology data (Fig. 5D) . Consistent with previous reports Zetterström et al., 2007; Brotherton et al., 2012) , levels of misfolded SOD1 were low or nondetectable in the insoluble fraction (Fig. 5A-C) .
Increasing spinal cord Cu via the Cu uptake transporter CTR1 improved the survival of SOD1G37R mice
To help assess the significance of Cu delivery in the protective activity of Cu II (atsm) in SOD1G37R mice, we aimed to increase spinal cord Cu levels via an alternate method. This was achieved by crossing SOD1G37R mice with mice that express the gene for the human Cu uptake transporter CTR1. The expression of hCTR1 in the spinal cord tissue (Fig. 6A ) induced a 19% increase in spinal cord Cu levels without altering levels of Zn or Fe (Fig.  6B) . Expression of endogenous mCtr1 was not altered by the expression of hCTR1 (Fig. 6A) . The elevation in spinal cord Cu levels translated into a modest (but statistically insignificant) improvement in locomotor function (Fig. 6C ) and a significant ( p ϭ 0.006) 12% increase in the median survival time of SOD1G37R mice (Fig. 6D) .
Discussion
Early studies showed that higher levels of expressed mutant SOD1 correlate with more rapid onset and progression of disease symptoms in the ALS model mice (Gurney et al., 1994; Wong et al., 1995; Dal Canto and Gurney, 1997) . This correlation is substantiated by delayed symptoms in ALS mice due to decreased mutant SOD1 levels (Ralph et al., 2005; Urushitani et al., 2007; Henriques et al., 2010) . Because of this clear apparent relationship between mutant SOD1 levels and the phenotype of the mice, we measured SOD1 in the spinal cords of Cu II (atsm)-treated SOD1G37R mice. Despite the fact that Cu II (atsm) treatment improved mouse locomotor function and survival (McAllum et al., 2013;  Fig. 1A ), we found that it significantly increased the mutant protein in vivo (Fig. 2) , thereby disproving the assertion that the phenotype of mutant SOD1 mice is proportional to levels of the mutant protein.
Mass spectrometry analyses indicated that Cu II (atsm) promoted conversion of metal-deficient SOD1 to holo-SOD1 (Fig.  2D-F ) via in vivo transfer of Cu from Cu II (atsm) to the mutant SOD1; the Cu content of SOD1 was increased (Fig. 4A) and 65 Cu from orally administered 65 Cu II (atsm) was recovered in spinal cord SOD1 (Fig. 4D) . These outcomes are consistent with the high stability of holo-SOD1 (Forman and Fridovich, 1973) , regardless of the presence of ALS-associated mutations (Banci et al., 2007) , and support the findings of in vitro studies that indicate SOD1 toxicity can be prevented by improving the metallation state of the protein (Estévez et al., 1999) . These outcomes indicate that the metal content of SOD1 may be a greater determinant of the toxicity of the protein in mutant SOD1-associated forms of ALS than the mutations themselves.
A number of mechanisms have been proposed to explain how an altered metal content of SOD1 may cause ALS. One of these involves pro-oxidant gain of function for Zn-deficient SOD1 , nondetectable levels in the insoluble fraction using these antibodies. D, Representative histology images for misfolded SOD1 immunoreactivity in spinal cord transverse sections using the B8H10 antibody (top row) and the C4F6 antibody (bottom row). Immunoreactivity using the A5C3 antibody was not detected by histology (data not shown). E, Immunoreactivity for the three antibodies was not detected in nontransgenic mice, indicating specificity for the human mutant form of the protein. n ϭ 4 -5 for all treatment groups. Error bars in A-C represent the SEM. (Crow et al., 1997) . This proposed toxic gain of function requires the retention of Cu in Zn-deficient SOD1, as it is the redox activity of Cu that catalyzes the production of reactive oxygen and nitrogen species (Crow et al., 1997; Estévez et al., 1999; Sahawneh et al., 2010) . This toxic mechanism of action is supported by a number of lines of evidence (Estévez et al., 1999; Roberts et al., 2007; Sahawneh et al., 2010) , and although the Zn-deficient pool of SOD1 accounts for only Ͻ1% of SOD1 in the SOD1G37R (Fig. 2E) , our data show that the concentration of Zndeficient SOD1 in spinal cord tissue is higher than concentrations that induce motor neuron toxicity in vitro (Sahawneh et al., 2010) . However, SOD1 mice in which all four Cu-coordinating histidine residues in the mutant SOD1 are removed have been developed, and these mice still develop ALS-like symptoms (Wang et al., 2003) . While the phenotype of these "quad mutant" mice does not exclude the Cu-mediated SOD1 toxicity occurring via Cu that binds to the SOD1 Zn-binding site (Valentine et al., 1979) , the absence of any significant changes to the pool of Zndeficient SOD1 in Cu II (atsm)-treated SOD1G37R mice indicates that the modulation of Zn-deficient SOD1 is not part of the therapeutic mechanism of action for Cu II (atsm). Metal-free (apo) SOD1 readily misfolds and aggregates (Arnesano et al., 2004; Lynch et al., 2004; Furukawa et al., 2008; Durazo et al., 2009; Rumfeldt et al., 2009; Tiwari et al., 2009) , thus potentially giving rise to the SOD1 aggregates present in some forms of ALS. Significantly, ALS-causing SOD1 mutations promote SOD1 misfolding via a pathway in which the mutant SOD1 preferentially loses Cu (Ip et al., 2011) , and restoration of the full metal compliment of the protein makes it relatively indistinguishable from holo wild-type SOD1 (Banci et al., 2007) . However, despite this relationship between Cu deficiency and SOD1 misfolding, preventing the formation of misfolded SOD1 is not the mechanism through which Cu II -(atsm) improved the locomotor function and survival of SOD1G37R mice, as none of the antibodies used to assess the levels of misfolded SOD1 revealed a decrease in the pool of misfolded SOD1 (Fig. 5A-D) . In fact, all three antibodies indicated that the soluble pool of misfolded SOD1 increased in equilibrium with the total pool of SOD1 ( Fig. 2A) . Previous studies have shown that decreasing the levels of misfolded SOD1 improves the survival and locomotor function of mutant SOD1 mice, suppresses inflammatory responses, and protects spinal cord motor neurons (Gros-Louis et al., 2010; Liu et al., 2012), outcomes that were all detected in Cu II (atsm)-treated SOD1G37R mice (Fig. 1) . Without precluding the potential contribution of methodological differences between the studies, these apparent disparate outcomes may indicate that SOD1-mediated dysfunction in ALS is not due to a single toxic species of SOD1, and that misfolded SOD1 contributes only partially to the decreased neuron functionality in ALS. Supporting this, none of the therapeutic interventions tested to Figure 6 . Effects of expressed hCTR1 on the locomotor function and survival of SOD1G37R mice. A, Levels of mRNA for hCTR1 and mCtr1 in the spinal cords of hCTR1 mice and nontransgenic (non-Tg) littermates. hCTR1 levels are expressed relative to levels of the endogenous mCtr1, and levels of mCtr1 are expressed relative to levels of endogenous mActb. B, Copper, zinc, and iron content of spinal cord tissue from mice expressing hCTR1 compared with nontransgenic littermates, as determined using LA-ICPMS as in Figure 3 . n ϭ 6 for both genotypes in A and B. C, Locomotor function of SOD1G37R and hCTR1xSOD1G37R mice measured as the latency to fall on the rotarod assay (n ϭ 14 SOD1G37R mice, n ϭ 8 hCTR1xSOD1G37R mice). D, Fraction of SOD1G37R and hCTR1xSOD1G37R mice alive relative to age (n ϭ 24 SOD1G37R mice, n ϭ 8 hCTR1xSOD1G37R mice). Regardless of genotype, mice were culled when complete paralysis was present in at least one hindlimb and were unable to right themselves within 15 s after being laid down on their side. Asterisks indicate the statistical significance (*p Ͻ 0.05). Error bars represent the SEM. Schematic to indicate how both chelation and supplementation therapeutic strategies can attenuate SOD1 toxicity. Apo-and holo-SOD1 are nontoxic; apo-SOD1 is rapidly turned over, whereas holo-SOD1 is the stable, functional antioxidant form. Toxicity of the labile, metal-deficient intermediate can be prevented by chelating agents that convert holo-SOD1 to apo-SOD1, or by agents such as Cu II (atsm), which convert apo-SOD1 to holo-SOD1.
date, including Cu II (atsm), has completely prevented death or locomotor deficits in ALS model mice.
SOD1 that is relatively Cu deficient and Zn replete has been reported in the spinal cords of ALS model mice (Lelie et al., 2011) and is supported by data shown in Figure 4C . Our observation that Cu-deficient SOD1 was the only pool of SOD1 decreased by Cu II (atsm) indicates that if the phenotype of the SOD1G37R mice is driven solely by mutant SOD1, increasing bioavailable Cu in the spinal cord is beneficial because it decreases the abundance of the Cu-deficient pool of SOD1. This is supported by data showing that the overexpression of CTR1 improves the survival of SOD1G37R mice (Fig. 6) , and by data showing that Cu administered orally as Cu II (atsm) is recovered in spinal cord SOD1 (Fig.  4D) . However, modulating the levels of spinal cord Cu to treat mutant SOD1 mice has been investigated previously, and the outcomes often indicate that decreasing Cu is beneficial. Treatment with ammonium tetrathiomolybdate, for example, is effective in mutant SOD1 mice via a mechanism proposed to involve attenuation of the Cu dyshomeostasis caused by mutant SOD1, and is supported by data that show the treatment decreases the levels of spinal cord Cu and removes Cu from the SOD1 active site (Tokuda et al., 2008 (Tokuda et al., , 2013 . Conversely, treating mutant SOD1 rats with pyrrolidine dithiocarbamate, a compound capable of increasing Cu levels in CNS tissue (Malm et al., 2007) , accelerated the ALS-like phenotype of mutant SOD1 rats . Targeting metal ion homeostasis, therefore, has good in vivo support as a strategy for treating ALS, but the interpretation of outcomes from studies that use notional metal-chelating agents, as opposed to metal delivery agents, is complicated by an incomplete understanding of the activity of these compounds at the cellular level, as was recently reviewed (Crouch and Barnham, 2012) .
Other studies have attempted to modulate disease symptoms in mutant SOD1 mice by genetic modification of Cu transporters and chaperones. The first of these studies used mice that had no Cu chaperone for SOD1 (CCS), a cellular chaperone that delivers intracellular Cu to SOD1. The SOD1/CCS Ϫ/Ϫ mice had decreased Cu levels in SOD1 but did not have an altered phenotype, thus generating the conclusion that the Cu content of mutant SOD1 did not contribute to SOD1 toxicity in vivo . This interpretation has been criticized (Beckman et al., 2002; Kiaei et al., 2004) based on data that show CCS is not the only chaperone that delivers Cu to SOD1 (Carroll et al., 2004) . By contrast, mice that express mutant SOD1 and a dysfunctional Cu-transporting ATPase 1 (ATP7A) displayed increased survival and locomotor function relative to mutant SOD1 mice with functional ATP7A, and it was shown that the expression of the dysfunctional ATP7A significantly decreased global levels of spinal cord Cu (Kiaei et al., 2004) . Also, the overexpression of CCS in mutant SOD1 mice dramatically accelerates disease onset and premature death (Son et al., 2007) . Data from the CTR1-overexpressing mice (Fig. 6 ) support the outcomes from our Cu II (atsm) studies, but on face value appear to oppose outcomes from mice with altered CCS or ATP7A functionality. Fundamental differences between the Cu transporters and chaperones modulated in these studies and their likely differing effects with respect to metallo-proteins other than SOD1 will have contributed to these apparent opposing outcomes. If anything, these studies demonstrate the often underestimated complexity of biometal metabolism. More information on how the metal content of SOD1 and other cupro-proteins is changed in these models is needed to reconcile these disparate outcomes.
While the definitive roles for altered Cu and Zn homeostasis in the toxic gain of function of SOD1 continue to be debated, the suboptimal metal content of SOD1 is nonetheless emerging as an important factor with excellent potential for therapeutic intervention. Our data indicate that Cu II (atsm) may mediate its protective effects, at least in part, by delivering Cu to Cu-deficient SOD1, thereby converting it to stable, nontoxic holo-SOD1. This therapeutic strategy does not preclude the potential benefits of removing Cu from, for example, Zn-deficient SOD1 to prevent a pro-oxidant gain of function. When considered with outcomes from previous studies, our data support the conclusion that at least part of the toxic gain of function of SOD1 resides in a metaldeficient intermediate, and that driving the protein toward holo-SOD1 via metal delivery or toward apo-SOD1 via sequestration appears to have comparable therapeutic potential (Fig. 7) . Our data add support to the strengthening hypothesis that combination therapy is likely to provide the best outcomes for patients with ALS.
